Late-stage biopharmaceutical company developing drug candidates for rare and orphan diseases
Late-stage biopharmaceutical company developing drug candidates for rare and orphan diseases. Its lead clinical assets use novel drug formulations and delivery methods to improve existing therapies, including an intravenous infusion for aneurysmal subarachnoid hemorrhage, an oral mucosal spray for ataxia-telangiectasia, and a topical spray for postherpetic neuralgia.